Krystal Biotech, Inc.

First two patients enrolled in Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa.  PITTSBURGH, Aug. 06, 2018 (GLOBE NEWSWIRE) — Krystal Biotech (NASDAQ:KRYS), a gene therapy company advancing  “off-the-shelf” topical and intra-dermal treatments for skin diseases, today reported financial results for the second quarter ended […]

PITTSBURGH, July 16, 2018 (GLOBE NEWSWIRE) — Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and intradermal “off-the-shelf” treatments for rare dermatological diseases, today announces a presentation on the Company’s lead product candidate, KB103, the first-ever topically-applied gene therapy being developed for the treatment of dystrophic epidermolysis bullosa (DEB). The presentation will […]

PITTSBURGH, May 24, 2018 (GLOBE NEWSWIRE) — Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and intradermal “off-the-shelf” treatments for rare dermatological diseases, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to KB103 for the treatment of dystrophic epidermolysis bullosa (DEB). KB103 is the first-ever […]